trial
as of 2026-07-01Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
NCTId NCT00690235
at a glance
Phase 4 · Completed
Enrollment 33 (actual)
Sponsored by University of Texas Southwestern Medical Center
Primary completion 2011-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-11
Primary completion
2011-08
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
University of Texas Southwestern Medical CenterLead Sponsor
Amylin Pharmaceuticals, LLC.Collaborator
Investigators
1
Carol A Tamminga, MDPrincipal Investigator
Sites
1 total
Dallas, United States
Facts & assertions
4 sourced
Enrollment
33
Phase
PHASE4
Primary Completion Date
2011-08
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person